Size-reductive Neoadjuvant Immunotherapy using Imiquimod in Squamous Cell Carcinoma of the Lower Lip.
- Author:
Hyo Seung SHIN
1
;
Sang Eun MOON
;
Kwang Hyun CHO
;
Chang Hun HUH
Author Information
- Publication Type:Case Report
- Keywords: Imiquimod; Immunotherapy; Lip; Neoadjuvant treatment; Squamous cell carcinoma
- MeSH: Aged, 80 and over; Carcinoma, Squamous Cell*; Cicatrix; Congenital Abnormalities; Female; Humans; Immunotherapy*; Lip*; Neoadjuvant Therapy; Neoplasm Metastasis; Skin Neoplasms
- From:Annals of Dermatology 2007;19(2):75-80
- CountryRepublic of Korea
- Language:English
- Abstract: rcinoma (SCC) is the second most common skin cancer. In particular, invasive SCC has a high risk of metastasis and sometimes, this can be fatal. At present, the treatment of choice for invasive SCC is complete excision with a proper surgical margin, but most cases of SCC develop on cosmetically-sensitive areas, so sometimes significant scarring or deformities can lead to an unhappy result. An 80 year-old female presented with a 4x1.5cm sized SCC on her lower lip. Although surgery was the first line therapy for this invasive SCC, a cosmetically poor outcome was expected. Thus the patient did not want to undergo a surgical operation, so we had to explore other treatment options. Recently there have been many reports that show imiquimod 5% cream is effective in the treatment of invasive SCC. Therefore we started topical therapy with imiquimod 5% cream five times a week. After 6 months, the lesion size was reduced to 2x1.5cm and we could remove the remnant tumor by wedge resection with cosmetically acceptable result. We suggest this neo-adjuvant immunotherapy can be an alternative for the treatment of cosmetically-critical SCC and present this case as a good example that has shown successful size-reductive neoadjuvant immunotherapy using imiquimod in invasive SCC.
